ALNEV.PA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 17:13):

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France...

Stats
Šios dienos apimtis	12 687.00
Vidutinė apimtis	755 945
Rinkos kapitalizacija	103 958
EPS	0 ( 2019-10-02 )
Last Dividend	0 ( N/A )
Next Dividend	0 ( N/A )
P/E	0
ATR14	0.00600 (2.33%)

Neovacs SA Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Neovacs SA Finansinės ataskaitos

Annual	2022
Pajamos:	1 112.00
Bruto pelnas:	-3.43M (-308 866.37 %)
EPS:	-117.60

FY	2022
Pajamos:	1 112.00
Bruto pelnas:	-3.43M (-308 866.37 %)
EPS:	-117.60

FY	2021
Pajamos:	22 595.00
Bruto pelnas:	-462 306 (-2 046.05 %)
EPS:	-7 841.13

FY	2020
Pajamos:	30 142.00
Bruto pelnas:	-89 853.00 (-298.10 %)
EPS:	-4 068.95

Financial Reports:

No articles found.

Neovacs SA

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.